Effect of terfenadine on the plasma concentrations of substance P and vasoactive intestinal polypeptide in volunteers

Abstract

The effect of terfenadine on the plasma concentrations of substance P and vasoactive intestinal polypeptide (VIP) was studied in 7 healthy subjects and 8 subjects with the common cold. Before terfenadine administration, the mean plasma substance P concentration of the subjects with the common cold was significantly higher than that of the healthy subjects. The increased mean plasma substance P concentration of the subjects with the common cold was decreased after terfenadine administration. In the healthy subjects, the mean plasma substance P concentration was unchanged by terfenadine administration. The mean plasma VIP concentration of the subjects with common cold was slightly higher than that of the healthy subjects before and after terfenadine administration, with no significant difference.

Endothelium‐dependent contraction in intrapulmonary arteries: mediation by endothelial NK1 receptors and TXA2

“…However, it is not clear whether SP released from the nerve endings diffuse to the endothelium and cause EDC. On the other hand, the concentration of SP in blood is not high enough to cause EDC (Mori et al, 1992). SP is localized in endothelial cells and released by hypoxia and change in flow (Milner et al, 1989;Ralevic et al, 1990).…”

Serum levels of substance P are decreased in patients with type 1 diabetes

“…There is evidence that SP is depleted in peripheral nerves in diabetes mellitus (Levy et al, 1989;Lindberger et al, 1989;Lysy et al, 1993;Schmidt et al, 1992), but despite of a small study in 11 diabetic patients (Kastrup et al, 1986), SP levels have not been measured in plasma or serum in diabetics so far. The study of Kastrup et al (1986) was performed by means of a radioimmunoassay which has (in a completely or partially identical way) also been used at that time by other groups in order to investigate SP levels for different reasons in nondiabetic patients (Conion et al, 1987;Marshall et al, 1990;Mori et al, 1992;Hegbrant et al, 1992;Valdemarsson et al, 1991).The aim of this study was a) to evaluate an enzyme immunoassay for detection of SP levels in serum and b) to investigate if SP levels in control subjects (n=75) differ from those of type 1 and type 2 diabetic patients (n=91).…”